SCHEMBL3116048

SCHEMBL3116048

Cc1cc(=O)n(-c2ccc(NC(=O)c3ccc(N(C)C)cc3)cn2)[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P4HTM Q9NXG6 2/20 0.54
▸ ORAI1 Q96D31 1/20 0.46
▸ RAB9A P51151 5/20 0.45
▸ NPC1 O15118 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ ROCK2 O75116 1/20 0.44
▸ ROCK1 Q13464 1/20 0.44
▸ MAPT P10636 5/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ KDM5A P29375 1/20 0.44
▸ KDM2B Q8NHM5 1/20 0.44
▸ KDM4C Q9H3R0 1/20 0.44
▸ KCNK3 O14649 2/20 0.44
▸ ALDH1A1 P00352 4/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ MCL1 Q07820 2/20 0.42
▸ HSD17B10 Q99714 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3120279 0.89 RAB9A (0.57) P4HTMRAB9ANPC1L3MBTL1MEN1
SCHEMBL3117426 0.89 ORAI1 (0.60) ORAI1RAB9ANPC1MEN1KMT2A
SCHEMBL3109283 0.88 PTPN1 (0.51) P4HTMRAB9ANPC1L3MBTL1KMT2A
SCHEMBL3116564 0.87 PTPN1 (0.50) P4HTMORAI1RAB9ANPC1L3MBTL1
SCHEMBL3117290 0.86 TRPV1 (0.47) RAB9ANPC1L3MBTL1MEN1KMT2A
SCHEMBL3117348 0.85 SMN1; SMN2 (0.58) RAB9AL3MBTL1MAPTCYP1A2CYP2C19
SCHEMBL3107074 0.84 CYP11B1 (0.46) RAB9ANPC1L3MBTL1MEN1KMT2A
SCHEMBL3122154 0.82 LMNA (0.52) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL14609473 0.80 ULK1 (0.47) ORAI1KMT2AMAPTKDM5AKDM2B
SCHEMBL3117708 0.80 KCNQ3 (0.56) RAB9ANPC1MEN1KMT2AROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100179161-A1 PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS ASTRAZENECA AB (SE) 2010-07-15 — — US disclosed
US-20100179161-A1 PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS ASTRAZENECA AB (SE) 2010-07-15 — — US disclosed
US-20100179161-A1 PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS ASTRAZENECA AB (SE) 2010-07-15 — — US disclosed
CN-101291923-A Pyrazolone derivatives for the treatment of tuberculosis ASTRAZENECA AB (SE) 2008-10-22 — — CN disclosed
WO-2007020426-A1 PYRAZOLONE DERIVATIVES FOR THE TREATMENT OF TUBERCULOSIS ASTRAZENECA AB (SE) 2007-02-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179161-A1 PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS TREH, TYMP, EPX P4HTM 1951/4885ORAI1 4667/4885RAB9A 1358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback